cancer marker News
-
INCOGEN Completes NIH Funded BISTI Project
INCOGEN and its collaborators announced the completion of the five-year long clear cell renal cell carcinoma (ccRCC) project. This multidisciplinary project was funded by several National Cancer Institute Small Business Innovation Research (SBIR) grants and involved collaborations with the Mayo Clinic, Eastern Virginia Medical School, and Johns Hopkins University. It resulted in the development ...
-
Exosome Display Technology for Antibody Generation, Targeted Delivery, and Protein Array Screen
Scientists now have realized that exosomes, representing a novel mode of intercellular communication, contribute to a wide range of biological processes in health and disease including cancer. Especially, growing evidence shows that tumor-derived exosomes play critical roles in cancer. Exosomes and their cargos may serve as cancer prognostic markers, therapeutic targets or even as anticancer ...
-
Precision therapeutics continues dedicated support to the NOCC `walk to break the silence`
Precision Therapeutics will sponsor the Pittsburgh Chapter of the National Ovarian Cancer Coalition's "Walk to Break the Silence" on Sunday, September 12, 2010. The walk, which takes place at the North Park Boathouse, is an optional 1 or 5 mile hike to benefit ovarian cancer awareness. Hoping that a great number of its employees will unite to help fortify the partnerships it has forged in ...
-
Manufacture of Carina’s LGR5 CAR-T has begun with CellVec contracted to produce GMP-grade lentivirus constructs
Singapore-based CellVec will manufacture clinical-grade lentivirus – the first critical step in making LGR5 CAR-T cells for a first-in-human clinical trial for patients with advanced colorectal (bowel) cancer in late 2022. Lentiviruses are widely used as a tool to deliver genes of interest to cells. In this case, the lentivirus transduces (or inserts) a group of genes to a patient’s ...
-
BIOMARK’s GLIOBLASTOMA Study Published in CANCERS Demonstrates Inhibiting SAT1 sensitized cancer cells towards radiation and chemotherapy
Vancouver, British Columbia – (October 27th, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the publication of a preclinical study demonstrating therapeutic capabilities of its SAT1 cancer marker in glioblastoma (GB) ...
-
PARIS Test Identified Effective Therapy for Patient with Terminal Ovarian Cancer
SEATTLE, Sept. 13, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine announces dramatic results for a 52-year-old patient with terminal ovarian cancer who received the PARIS® Test in early summer 2020. An interim case summary was included in SEngine’s poster presentation at the AACR 2021 annual meeting. The patient’s oncologist, Heidi Gray, MD, who specializes in ovarian cancer ...
-
Avelas Makes Senior Appointments and Provides Update on Pegloprastide Phase III Clinical Program
Ambareen Sheriff appointed as Vice President, Regulatory and Quality and Robin Stevens appointed as Non-Executive Director Novel, best-in-class agent for visualizing breast cancer margins to enter Phase III trial in 1H22 SAN DIEGO, CA – Avelas Biosciences, Inc. (“Avelas” or “the Company”), a clinical-stage drug-device company pioneering the field of fluorescence ...
-
Carina Biotech appoints Cell Therapies to undertake manufacture of LGR5 CAR-T cells for clinical trial
Highlights Melbourne-based contract development and manufacturing organisation Cell Therapies will manufacture Carina Biotech’s LGR5 CAR-T cells for a first-in-human clinical trial for patients with advanced colorectal (bowel) cancer. Carina’s CAR-T cells are targeted at LGR5, a cancer stem cell marker that is highly expressed on colorectal cancer and other cancers. Colorectal ...
-
Carina Biotech submits LGR5 CAR-T pre-IND (Investigational New Drug) package to the US Food & Drug Administration
Carina Biotech is very pleased to announce that we have submitted a pre-IND (Investigational New Drug) application to the US FDA (Food & Drug Administration) for our CAR-T therapy that targets a cancer stem cell antigen known as LGR5. This represents a major step towards taking our CAR-T cell (CNA3103) into a Phase I/IIa clinical trial in patients with advanced colorectal (bowel) cancer ...
-
Carina Biotech raises $5.4 million to ready LGR5 CAR-T program for advanced colorectal cancer for the clinic
Carina Biotech is delighted to announce it has raised AU$5.4 million. The raise was strongly supported by current shareholders, board and management and attracted new institutional and impact investors including a cornerstone investment from the Minderoo Foundation. The funding will enable us to undertake the required studies to initiate a clinical trial of our lead LGR5-targeted CAR-T program ...
-
Avelas Announces Top-Line Data Showing Pegloprastide (AVB-620) Can Significantly Improve Cancer Detection in Real-Time During Breast Cancer Surgery
Use of pegloprastide, a fluorescent cancer marker, during surgery correctly identified cancer in up to 75% of patients who may have otherwise been candidates for a repeat (re-excision) surgery Observed re-excision rate was ~6% in patients whose surgeries included pegloprastide; current re-excision rates are estimated at 20-40% among all patients receiving an initial lumpectomy Each year in the ...
-
Dako, an Agilent Technologies Company, Launches Two Ready-to-Use Antibodies for Cancer Diagnosis
Dako, an Agilent Technologies company and worldwide provider of cancer diagnostic solutions, today announced the addition of two new antibodies, Anti-CK 8/18 and Anti-TdT, to the Dako portfolio of high-quality reagents, instruments and software. Anti-CK 8/18 is the first rabbit monoclonal antibody cocktail for cytokeratin 8/18 (CK 8/18) available from a major pathology provider. It is used by ...
-
Carina Biotech to showcase its LGR5 CAR-T program at the American Association for Cancer Research (AACR) Annual Meeting
Carina has had five abstracts accepted for poster presentations at the AACR Annual Meeting which will take place from April 8 to April 13. The poster presentations come after Carina’s recent submission of a pre-IND package to the FDA for Carina’s LGR5 CAR-T cell for the treatment of patients with advanced colorectal cancer. Highlights Five conference abstracts will be presented ...
-
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2022 and provided a business and financial update. Second quarter Net Revenue was $9.4 million, a 16% decrease as compared to the same period of 2021. During the second quarter the Company was notified by Novitas, it’s CME ...
-
CD Genomics: Targeted Proteomics Analysis Service Now Available by Bioinformatics-Analysis Platform
Bioinformatics-analysis Platform belongs to CD Genomics, which provides reliable next-generation and third-generation high-throughput sequencing data analysis, comprehensive technology services, database construction, and other related data analysis business. The platform is a leading open solution for data-driven innovation, which aims to discover hidden potential in biological data and unearth ...
By CD Genomics
-
Transgene and NEC Announce Positive Preliminary Data From Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
TG4050 induced robust anti-tumor cellular immune responses against multiple neoantigen targets in all evaluable patients (4/4). TG4050 monotherapy was also associated with the first signs of clinical activity. TG4050 was well tolerated, with no related Serious Adverse Events reported across the two studies to date. Additional patients are being enrolled, with the aim to treat up to 43 ...
-
Study Demonstrate Superiority of VeraForm® Marker Over Clips
Study Demonstrate Superiority of VeraForm® Marker Over Clips For Tumor Bed Delineation Accuracy San Francisco CA, October 28, 2021- Videra Surgical Inc., the developer of the novel adaptable tumor bed marker VeraForm® for breast cancer surgery, announced the presentation of an independent study at this week’s ASTRO conference in Chicago and the American College of ...
-
Creative Proteomics Cytokine Accelerates Your Project with Its Colony Stimulating Factor Detection Service
The Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently announced the launch of the colony stimulating factor detection platform for scientific research. ...
-
Creative Proteomics Cytokine Boosts Your Research and Discovery with Mouse Cytokine Assay
The Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently launched the Mouse Cytokine Assay with high sensitivity to support research in immune responses, inflammatory ...
-
CD Genomics: The Biomedical Bioinformatics Platform Unveils Biomarker and Target Discovery Data Analysis Service
The Biomedical Bioinformatics Platform belongs to CD Genomics and has a good reputation for assisting researchers with data analysis challenges, including NGS data processing, analysis, interpretation, and general genomic data analysis, as well as data mining, statistical modeling, data integration, information science, database construction, and management. Recently, the company announced the ...
By CD Genomics
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you